NEW YORK, July 9, 2019 /PRNewswire/ — Wolters Kluwer Legal & Regulatory U.S. continues to expand its leadership in securities law with the launch of Capital Markets Clause Analytics, a workflow solution that combines the power of artificial intelligence with curation by expert attorneys. The solution, which is the latest addition to Wolters Kluwer’s acclaimed Transactional Law Suite for Securities, sets a new standard for transforming the capital markets document drafting workflow for attorneys and securities professionals.
By providing access to a database of Debt and Equity Agreements and their ancillary documents, Capital Markets Clause Analytics dramatically streamlines the drafting process for legal professionals. The workflow solution provides a comprehensive database of articles and clauses that appear in Capital Markets agreements, giving users insight and guidance into accepted standards to apply to their own agreements. Legal professionals can view the commonality and variability of specific articles and clauses within an agreement and compare specific clauses to the standard language used in clauses of that type.
Building on Wolters Kluwer’s market-leading content and solutions for transactional law, Capital Markets Clause Analytics leverages powerful analytical tools to empower users to:
“As clients continue to aggressively pursue improved cost efficiency and timeliness from legal providers, legal professionals are in need of workflow solutions that address their most critical pain points,” said Susan Chazin, Esq., Portfolio Director for Securities and Banking at Wolters Kluwer Legal & Regulatory U.S. “We developed Capital Markets Clause Analytics to integrate powerful technology with our domain expertise to transform the Capital Markets drafting process, boost our customers’ productivity and improve their ROI.”
Capital Markets Clause Analytics streamlines the Capital Markets drafting and negotiating process for securities law professionals with:
To learn more about the Capital Markets Clause Analytics and the power of the entire Transactional Law Suite for Securities, visit: https://lrus.wolterskluwer.com/store/capital-markets-analytics/ and https://lrus.wolterskluwer.com/store/transactional-law-suite/.
About Wolters Kluwer Legal & Regulatory U.S.
Wolters Kluwer Legal & Regulatory U.S. is a part of Wolters Kluwer N.V. (AEX: WKL), a global leader in professional information, software solutions, and services for the healthcare; tax and accounting; governance, risk and compliance; and legal and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2018 annual revenues of €4.3 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
For more information about Wolters Kluwer Legal & Regulatory U.S., visit www.WoltersKluwerLR.com, follow us on Facebook, Twitter and LinkedIn.
Media
Linda Gharib
Director, Communications
Wolters Kluwer Legal & Regulatory U.S.
Tel: +1 (646) 887-7962
Email: lrusmedia@wolterskluwer.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/wolters-kluwer-launches-ai-enhanced-capital-markets-clause-analytics-to-improve-quality-and-efficiency-of-drafting-and-negotiating-capital-markets-agreements-300881736.html
SOURCE Wolters Kluwer Legal & Regulatory U.S.
- Revenue increase of over 600%Dallas, Georgia--(Newsfile Corp. - July 2, 2024) - Bemax Inc.…
VANCOUVER, BC / ACCESSWIRE / July 2, 2024 / 1933 Industries Inc. (the "Company" or…
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a…
SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a…
The ceremony will be held in celebration of Scilex’s launch of GLOPERBA®, an innovative non-opioid…
July 2, 2024 Biodexa Pharmaceuticals PLC Positive Phase 1 Clinical Data of MTX110 in DMG…